181 180 Additional paid-in capital 4,854,814 4,832,707 Company common stock held by Nonqualified Deferred Compensation Plan (9,832) (9,961) Accumulated other comprehensive income 34,127 20,164 Accumulated deficit (1,639,328) (1,720,709) Total stockholders' equity 3,239,962 3,122,381 Total liabilities and stockholders' equity $ 4,722,841 $ 4,690,039  (1) December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2020.The sale is reflected in the Company's consolidated financial statements for the three months ending March 31, 2020; and as a result of the transaction BioMarin will not recognize Net Product Revenues from Firdapse in the future.